One dated view of the VK2735 evidence base, keeping the subcutaneous and oral formulations separate — the peer-reviewed subcutaneous VENTURE Phase 2, the oral VENTURE topline, the subcutaneous maintenance study and its oral follow-on, the pending Phase 3 VANQUISH trials, and the newly registered oral Phase 3 SUNRISE trials. Evidence state comes before headline magnitude.
VK2735, a dual GLP-1/GIP receptor agonist, remains investigational and is not approved; subcutaneous Phase 3 VANQUISH is ongoing, and Viking announced on 14 October 2026 that it had initiated the oral Phase 3 SUNRISE program, whose trials were first posted on ClinicalTrials.gov on 9 October 2026. At its 16 October 2026 update, ClinicalTrials.gov still listed both trials as not yet recruiting, with an estimated start in November 2026. This tracker is research context, not clinical or personal-use guidance.
The statuses below describe the source available for each result, not an approval status or a judgment about clinical use.
Adults with obesity or overweight · Phase 2 · 13 weeks · subcutaneous, weekly
Published in Obesity, once-weekly subcutaneous VK2735 produced mean body-weight reductions of up to 14.7% (up to 13.1% placebo-adjusted) at week 13, meeting all endpoints, with up to 88% of treated patients losing at least 10% versus 4% with placebo (n=176, NCT06068946).
Adults with obesity or overweight · Phase 2 · 13 weeks · oral, daily
In company data presented at ECO 2026, once-daily oral VK2735 produced dose-dependent mean body-weight reductions of up to 12.2% at week 13, with up to 80% of participants losing at least 10% and up to 97% at least 5%, versus 5% and 10% with placebo. A peer-reviewed publication was not identified at this tracker’s review (n=280, NCT06828055).
Obesity without type 2 diabetes · Phase 3 · 78 weeks · subcutaneous
The registrational subcutaneous Phase 3 trial is fully enrolled (about 4,500) with an estimated primary completion in 2027. Detailed results were not identified as released at this tracker’s review (NCT07104500).
Obesity with type 2 diabetes · Phase 3 · 78 weeks · subcutaneous
The registrational subcutaneous Phase 3 trial in type 2 diabetes completed enrollment (about 1,000) in early 2026, with an estimated primary completion in 2027. Detailed results were not identified as released at this tracker’s review (NCT07104383).
Adults with obesity · Phase 1 · randomized, double-blind, placebo-controlled · 33 weeks · subcutaneous
In about 180 adults, 21 weeks of weekly subcutaneous VK2735 produced about 16–19% weight loss versus about 0% with placebo. Participants then switched for 12 weeks to monthly or every-other-week injections or placebo; the monthly arms kept 82–90% and the every-other-week arms 83–97% of their week-21 weight loss, versus 61% with placebo. A small exploratory cohort that continued weekly treatment (n=13) reached 21.7% at week 33. Weight endpoints were exploratory. The study is registered as a Phase 1 trial (VK2735-102, NCT07838740, first posted 24 September 2026); no peer-reviewed publication was identified at this tracker’s review.
Adults with obesity · Phase 1 · randomized, double-blind, placebo-controlled · 33 weeks · subcutaneous induction, then oral or subcutaneous maintenance
Viking started Part 2 on 6 October 2026 in about 195 adults: after the same 21-week subcutaneous induction, participants move to daily oral tablets, further subcutaneous regimens or placebo. Viking corrected its 6 October release on 14 October 2026: the trial does not test weekly oral doses. Viking expects results in 2027.
Obesity, and obesity with type 2 diabetes · Phase 3 · oral
Viking’s oral VK2735 Phase 3 trials were first posted on ClinicalTrials.gov on 9 October 2026 (submitted 5 October): SUNRISE 1 in weight management (NCT07868835) and SUNRISE 2 in adults with type 2 diabetes (NCT07868939). Viking announced on 14 October 2026 that it had initiated the SUNRISE Phase 3 program. SUNRISE 1 includes adults with obesity or overweight without type 2 diabetes. Each placebo-controlled trial runs 68 weeks and targets about 560 adults. At its 16 October 2026 update, ClinicalTrials.gov still listed both trials as not yet recruiting, with an estimated start in November 2026 and estimated primary completion in July 2028 and October 2028.
How to read this tracker
A full report has passed journal review and exposes methods and analyses for scrutiny.
A primary-source company release is available, but the complete paper may not yet be published.
The registry establishes design and status; it does not substitute for a results publication.